1. Tesla reported Q4 earnings that missed estimates, but investor sentiment was lifted by Elon Musk's optimistic projections, including a $10 trillion revenue potential from robots. 2. Despite valuation concerns, the author upgrades the rating to speculative Buy due to bullish chart setup and Musk's ambitious growth projections. 3. Tesla's cost advantage in autonomous vehicles and potential rapid scaling of Optimus robots support long-term growth.

1. The author anticipates the FDA will soon declare the semaglutide shortage resolved, potentially slowing Hims' revenue growth rate due to compounding restrictions. 2. He foresees explosive revenue growth post-FDA announcement due to 60-day timelines for pharmacies (503A) and 90-day timelines for outsourcing facilities (503B) to comply with the restrictions. 3. The author believes HIMS may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings, creating uncertainty for speculators betting against the stock. 4. The author rates Hims as a 'Hold' due to limited upside for a long position and too much uncertainty to justify initiating a short position at this time.

1. Suncor Energy and Enbridge are two of Canada's most discussed oil stocks. Suncor has a stronger balance sheet and better valuation, profitability, and growth metrics. 2. Enbridge is less sensitive to oil price volatility compared to Suncor. 3. Assuming oil prices remain above $60 for the next five years, Suncor is expected to deliver more value to shareholders than Enbridge.

1. Applied Materials is a high-quality company with strong fundamentals and impressive financial growth. 2. Despite its long-term growth potential, AMAT's current valuation is elevated, limiting short-to-medium-term margin of safety. 3. The semiconductor manufacturing equipment market is expected to grow, supporting AMAT's EPS growth. 4. The author recommends holding off on buying AMAT stock now, expecting better entry points in future downturns.

1. Intel's market cap has stagnated for 30 years, but deep value exists due to its core CPU segment and potential for a turnaround; 2. The CPU market remains profitable with limited competition, and any improvement in Intel's other businesses could create significant value; 3. Whether the M&A happens or not, this could have strategic changes or management shake-ups at Intel that benefit shareholders.

1. TransMedics' stock has dropped 47% since October 2024 due to missed earnings and reduced revenue guidance. 2. Despite the valuation drop, high expectations remain for 15% FCF margins and 21% YoY revenue growth. 3. The company has significant debt and needs to navigate profitability and sustained growth to justify valuation.

1. Realty Income Corporation's share price has dropped by 20% in the past three months; 2. The stock is now at its lowest point since the bear market before the pandemic; 3. The article discusses whether it's a good time to buy the stock while it's cheap.

1. The article compares two major players in the Triple Net REIT space, Realty Income Corporation and NNN, focusing on their income-generating capabilities for shareholders. 2. It highlights the author's preference for maximizing income and the importance of sustainable income in retirement investing. 3. The author discusses the High Dividend Opportunities community and its investment strategies.

1. This article provides a weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. 2. It highlights companies that have changed their dividends, those with upcoming ex-dividend dates, and companies with upcoming pay dates. 3. The author mentions additional resources available through The Dividend Kings marketplace service.

1. Liberty All-Star Equity has underperformed compared to a DIY portfolio using the SPY ETF, confirming the author's 2023 prediction. 2. Some US 'value' managers hold high P/E stocks, making the fund vulnerable to market shocks. 3. The author recommends high-yield alternatives like QDPL and JAAA for better returns. 4. Given the fund's poor historical performance and high valuations, the author advises a relative sell and better-performing alternatives.

1. Rigetti Computing's speculative valuation led to a nearly 50% price drop after Nvidia's CEO commented on the distant scalability of quantum computing; 2. The article argues that Rigetti's fundamentals don't justify its valuation; 3. The author estimates a fair value of $595M with a negative margin of safety, recommending avoiding the stock despite short-term momentum.

1. High-yield dividend stocks can be powerful income machines but also risky; 2. We discuss two 14%+ yielding stocks, one to buy and one to avoid; 3. High Yield Investor offers exclusive access to subscriber-only portfolios.

1. The S&P 500, Nasdaq, and Dow all saw significant gains in 2024; 2. Consumer spending continued to drive the economy with retail spending increasing; 3. Cryptocurrency trends, particularly Bitcoin, were a major focus with significant price fluctuations; 4. Geopolitical tensions and market uncertainty were highlighted by events in the U.S., Russia, and the Middle East.

1. Quantum-Si, a life sciences company, has been chosen as a quantum computing play due to its name, despite not being involved in the field. 2. Since its listing on Nasdaq, the company has burned through nearly $350 million and is far behind its original business plan. 3. Quantum-Si has extended its cash runway by raising additional funds, but is expected to lose momentum traders soon. A 'Sell' rating is initiated for its common stock.

1. The abrdn Healthcare Investors fund is rated 'sell' due to its mismatch with income investing and managed distribution plans; 2. The fund has underperformed the Nasdaq Biotechnology Index and iShares Biotechnology ETF, indicating its inability to generate alpha compared to more tax-efficient alternatives; 3. The fund's high yield is unsustainable, relying on capital gains and potentially forcing premature sales, which is not suitable for income-oriented investors.

1. Nvidia's 2024 financial performance was impressive, with revenues nearly doubling to $113 billion. 2. Intensifying competition from Broadcom, Marvell Technology, and AMD may challenge Nvidia's dominance in the AI hardware market in 2025. 3. Market saturation and cyclical demand fluctuations may slow Nvidia's growth, with revenue projections indicating a 40-50% increase next year.

1. Rigetti Computing has seen a massive increase in stock value over the past month due to investor excitement around quantum computing. 2. The company's financials show significant losses and a high cash burn rate, raising concerns about its long-term viability. 3. The stock is currently overvalued and trades at twice its price targets, suggesting a potential crash in the near term.

1. Viking Therapeutics' stock has dropped 25% despite Phase 2 promising results for VK2735 due to competition in the obesity treatment market; 2. Viking's financial health is strong with over $50 million in cash and $880 million in short-term investments; 3. The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, challenging Viking's differentiation and market share gain.

1. Alphabet Inc.'s stock is rising, but the market is ignoring secular risks. 2. The latest quarter showed 16% YoY revenue growth and a significant increase in cloud margins. 3. The stock's valuation at 22x earnings may already account for competitive headwinds, but further pressure on search revenue growth is anticipated. 4. The author prefers reallocating to stocks with better risk-reward profiles, like Meta Platforms, given the rising valuations and potential headwinds for GOOG.

1. Time Until Payback is a critical metric for evaluating investments, focusing on how long it takes to recoup the initial investment through earnings. 2. MercadoLibre's TUP is estimated at 12 years, making it relatively attractive compared to the S&P 500's 14-15 years. 3. Fast-growth stocks like MELI offer significant upside potential but come with higher volatility and a wider range of outcomes; patience and long-term holding are key.